Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. NovMetaPharma Co., Ltd.
  6. Summary
    A229500   KR7229500004

NOVMETAPHARMA CO., LTD.

(A229500)
 SummaryChartsNewsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
09/09/2021 09/10/2021 09/13/2021 09/14/2021 09/15/2021 Date
22650 22650 23200 23200 23300 Last
4410 2389 4853 794 1583 Volume
-1.52% 0.00% +2.43% 0.00% +0.43% Change
Company
NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about NOVMETAPHARMA CO., LTD.
08/20NovMetaPharma Co., Ltd. announced that it has received KRW 3 billion in fundi..
CI
08/18NovMetaPharma Co., Ltd. announced that it expects to receive KRW 3 billion in..
CI
2019NovMetaPharma Co., Ltd. announced that it has received KRW 4.511234288 billio..
CI
2019NovMetaPharma Co., Ltd. announced that it expects to receive KRW 4.511234288 ..
CI
2017NovMetaPharma Co., Ltd. announced that it has received KRW 1.86 billion in fu..
CI
2017NovMetaPharma Co., Ltd. announced that it expects to receive KRW 1.86 billion..
CI
More news
News in other languages on NOVMETAPHARMA CO., LTD.

- No features available -

More news
Chart NOVMETAPHARMA CO., LTD.
Duration : Period :
NovMetaPharma Co., Ltd. Technical Analysis Chart | A229500 | KR7229500004 | MarketScreener
Managers and Directors
Seon-Wook Hwang Chief Executive Officer & Director
Heon-Jong Lee Director, VP, Head-Research & Development
Mun-Gi Song Chief Technology Officer & Executive board member
Sang-Joon Kim Independent Director
Jong-Man Seol Independent Director